Work

Realizing Benefits of First‐in‐Class Generic Entry—The Case of SGLT2 Inhibitors

Year: 2026

Type: article

Abstract: Dr. Gondi reported employment at Health Strategy. Dr. Kesselheim and Dr. Rome reported receiving grants from the Elevance Health Public Policy Institute, Humana, and the PCMA Foundation and personal fees from Alosa Health outside the submitted work. Dr. Kesselheim also reports serving as an expert witness on behalf of a payor in a case against Teva regarding marketing of Copaxone and on behalf of a group of state attorneys general and payors in a case against multiple generic manufacturers related to alleged price fixing.

Source: Clinical Pharmacology & Therapeutics

DOI: 10.1002/cpt.70459

Authors: Suhas Gondi, Aaron S. Kesselheim, Benjamin N. Rome

Institutions: Harvard University, Massachusetts General Hospital, Brigham and Women's Hospital

Language: English

Topic: Pharmaceutical Economics and Policy

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W7204243804

FWCI:

Cites: 7

Cited by:

Related to: